BioNTech SE
BioNTech SE (BNTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bntx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BioNTech SE (BNTX) measures how much investors pay for each dollar of the company's trailing earnings. BNTX's current PE ratio of N/A is calculated by dividing its stock price of $88.08 by its TTM earnings per share of -$4.93.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%15.0x
MedianQ3 · 75%1033.2x
Max
At N/A, BNTX's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BioNTech SEYou BNTX | $22.3B | N/A | — | -$4.93 |
 Biogen Inc. BIIB | $28.8B | 19.96x | -9.7% | $8.82 |
 DexCom, Inc. DXCM | $28.1B | 30.97x | +40.0% | $2.14 |
 Genmab A/S GMAB | $15.4B | 19.86x | -10.2% | $1.55 |
 Incyte Corporation INCY | $20.5B | 14.98x | -32.2% | $6.59 |
 Natera, Inc. NTRA | $30.8B | N/A | — | -$1.52 |
 Koninklijke Philips N.V. PHG | $25.4B | 24.78x | +12.1% | $0.93 |
Industry Average 5 peers with valid PE | — | 22.11x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.51 | — | |
2024-12-31 FY2024 | — | $-2.77 | — | |
2023-12-31 FY2023 | 24.69x | $3.87 | +582.6% | |
2022-12-31 FY2022 | 3.62x | $38.78 | -32.7% | |
2021-12-31 FY2021 | 5.37x | $42.18 | -99.5% | |
2020-12-31 FY2020 | 1033.15x | $0.06 | — | |
2019-12-31 FY2019 | — | $-0.85 | — | |
2018-12-31 FY2018 | — | $-0.21 | — | |
2017-12-31 FY2017 | — | $-0.38 | — | |
2016-12-31 FY2016 | — | $0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BioNTech SE (BNTX) measures how much investors pay for each dollar of the company's trailing earnings. BNTX's current PE ratio of N/A is calculated by dividing its stock price of $88.08 by its TTM earnings per share of -$4.93.
Frequently asked questions
BNTX pe ratio · 6 questionsBNTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $88.08 and TTM EPS of -$4.93. Data sourced from Financial Modeling Prep via BNTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BioNTech SE SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08